These NGS panels target genes that are associated with multiple hematological conditions, e.g., DNMT3A, TET2, ASXL1, and genes that are implicated in the pathogenesis of specific hematological disorders, e.g., JAK2 for myeloproliferative neoplasms (MPN). This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.